Skip to main content

Table 4 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with chemotherapy

From: Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Study name/code (NCT)

Study phase

Type of Cancer

Treatment

Patients evaluated for response

Time to first tumor assessment (weeks)

ORR by RECIST 1.1 criteria

ORR by immune-related response criteria

Patients treated beyond progression

Response rate after initial PD

First author and date of publication

CheckMate-012

(NCT01454102)

1

NSCLC

Nivolumab plus standard chemotherapy

56

10a

24 (42.9%)

Not reported

Not reported

1 (1.8%)

Rizvi 2016 [80]

GP28328

(NCT01633970)

1b

Breast cancer

Atezolizumab plus chemotherapy

33

8

13 (39.4%)

Not reported

6 (18.2%)

3 (9.1%)

Adams 2019 [81]

PembroPlus

(NCT02331251)

1b/2

Pancreatic adenocarcinoma

Pembrolizumab plus gemcitabine and nab-paclitaxel

15

Not reported

3 (20.0%)

3 (20.0%)a

Not reported

0 (0.0%)b

Weiss 2017 [82]

NCI-2015-01310

(NCT02538510)

2

HNSCC and salivary gland cancer

Pembrolizumab plus vorinostat

50

9

12 (24.0%)

Not reported

12 (24.0%)

1 (2.0%)c

Rodriguez 2019 [83]

PEMBROSARC

(NCT02406781)

2

Sarcomas

Pembrolizumab plus CP

50

6

0 (0.0%)

1 (2.0%)

Not reported

1 (2.0%)

Toulmonde 2018 [84]

  1. Abbreviations: CP cyclophosphamide, HNSCC head and neck squamous cell carcinoma, NCT ClinicalTrials.gov Identifier, NSCLC non-small-cell lung carcinoma, ORR overall response rate, PD progressive disease, SD stable disease
  2. a Per the original study protocol, tumor response was first assessed at week 6. However, due to the chance of early pseudoprogression at this time point, the protocol was amended to perform the first tumor assessment at week 10
  3. b2 patients achieved immune-related SD after RECIST-defined PD
  4. can additional patient achieved > 6 months SD